Two types of TKI-based combination therapy have significantly higher risk of grade three and higher AEs than TKI alone.<h4>Conclusion</h4>1G EGFR-TKIs plus chemotherapy and osimertinib seem to be the two better options as first-line care in advanced NSCLC patients with EGFR-mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.